Cut from a different cloth: a new treatment for hyperhidrosis

The alternative to Botox is poised to hit the US market

A new drug to treat excessive underarm sweating has been approved for use by by the US Food and Drug Administration (FDA) as an alternative to Botox.


Glycopyrronium is a once-daily prescription treatment in the form of a cloth, indicated for primary axillary hyperhidrosis in patients from nine years of age.

Marketed under the brand name Qbrexza, the cloth is applied directly to the skin and designed to block sweat production by inhibiting sweat gland activation.

Common side effects of the anticholinergic include dry mouth, mydriasis, oropharyngeal pain, headache, blurred vision, pruritus, erythema, and dryness of the eye, throat, skin, and nose.

It should not be administered with other anticholinergic drugs.

Glycopyrronium is not approved for use in Australia.

Current treatments for hyperhidrosis here include Botox therapy, laser treatment and surgical removal of the sweat glands.